Loading icon
Press enter or spacebar to select a desired language.
Research
Press enter or spacebar to select a desired language.

PubMed COVID-19 Clinical Care

2881 - 2890 of 3602 results found

Evaluation of risk management in a natalizumab home infusion procedure

Date
Thursday, May 18, 2023 - 4:00 AM
Description
Natalizumab is a well-established disease-modifying therapy used in active multiple sclerosis (MS). The most serious adverse event is progressive multifocal leukoencephalopathy. For safety reasons, hospital implementation is mandatory. The SARS-CoV-2